Antiandrogens
Aspirin
Bamlaniv../e..
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Probiotics  COVID-19 treatment studies for Probiotics  C19 studies: Probiotics  Probiotics   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Melatonin (meta)
Aspirin (meta) Metformin (meta)
Bamlaniv../e.. (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Lactoferrin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   All Outcomes
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hospital discharge -12% Improvement Relative Risk Time to discharge -60% Time to viral- -35% c19probiotics.com/li10.html Favors probiotics Favors control
5 March 2021 - Late treatment study
The role of probiotics in coronavirus disease-19 infection in Wuhan: A retrospective study of 311 severe patients
Li et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107531 (Peer Reviewed)
Source   PDF   Share   Tweet
Retrospective 311 severe condition hospitalized patients in China, 123 treated with probiotics, showing slower viral clearance and recovery with treatment. Authors note that probiotics were able to moderate immunity and decrease the incidence of secondary infections.
risk of no hospital discharge, 11.8% higher, RR 1.12, p = 0.68, treatment 30 of 123 (24.4%), control 41 of 188 (21.8%).
time to discharge, 60.0% higher, relative time 1.60, p < 0.001, treatment 123, control 188.
time to viral-, 35.3% higher, relative time 1.35, p < 0.001, treatment 123, control 188.
Effect extraction follows pre-specified rules prioritizing more serious outcomes.
Li et al., 3/5/2021, retrospective, China, Asia, peer-reviewed, 7 authors, average treatment delay 13.0 days.
All Studies   All Outcomes
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Submit